Celldex Therapeutics Stock
Celldex Therapeutics Stock
Heavy losses for Celldex Therapeutics today as the stock fell by -€1.400 (-4.120%).
With 11 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 56 € shows a very positive potential of 71.78% compared to the current price of 32.6 € for Celldex Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | -4.120% | -2.976% | -7.386% | 9.396% | -9.945% | 42.110% | 513.936% |
| Vaxart Inc. | 0.400% | -4.511% | 13.140% | -32.982% | 47.789% | -85.987% | - |
| Larimar Therapeutics Inc. | 0.780% | 0.781% | 1.575% | 89.706% | 58.088% | -2.273% | -67.305% |
| aTyr Pharma Inc | -5.590% | -6.748% | 4.110% | -27.619% | 17.829% | -58.242% | -71.125% |
Comments
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat